{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T15:53:45Z","timestamp":1788537225405,"version":"build-2803163510"},"reference-count":62,"publisher":"MDPI AG","issue":"8","license":[{"start":{"date-parts":[[2024,4,19]],"date-time":"2024-04-19T00:00:00Z","timestamp":1713484800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Ministry of Education and Science of the Republic of Serbia","award":["200110"],"award-info":[{"award-number":["200110"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Diagnostics"],"abstract":"<jats:p>A challenging task in routine practice is finding the distinction between benign and malignant paragangliomas and pheochromocytomas. The aim of this study is to conduct a comparative analysis of angiogenesis by assessing intratumoral microvascular density (MVD) with immunohistochemical (IHC) markers (CD31, CD34, CD105, ERG), and S100 immunoreactivity, Ki67 proliferative index, succinate dehydrogenase B (SDHB) expressiveness, tumor size with one the most utilized score Pheochromocytoma of Adrenal Gland Scales Score (PASS), using tissue microarray (TMA) with 115 tumor samples, 61 benign (PASS &lt; 4) and 54 potentially malignant (PASS \u2265 4). We found no notable difference between intratumoral MVD and potentially malignant behavior. The group of potentially malignant tumors is significantly larger in size, has lower intratumoral MVD, and a decreased number of S100 labeled sustentacular cells. Both groups have low proliferative activity (mean Ki67 is 1.02 and 1.22, respectively). Most tumors maintain SDHB expression, only 6 cases (5.2%) showed a loss of expression (4 of them in PASS &lt; 4 group and 2 in PASS \u2265 4). PASS score is easily available for assessment and complemented with markers of biological behavior to complete the risk stratification algorithm. Size is directly related to PASS score and malignancy. Intratumoral MVD is extensively developed but it is not crucial in evaluating the malignant potential.<\/jats:p>","DOI":"10.3390\/diagnostics14080849","type":"journal-article","created":{"date-parts":[[2024,4,19]],"date-time":"2024-04-19T10:53:17Z","timestamp":1713523997000},"page":"849","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Comprehensive Investigation of Angiogenesis, PASS Score and Immunohistochemical Factors in Risk Assessment of Malignancy for Paraganglioma and Pheochromocytoma"],"prefix":"10.3390","volume":"14","author":[{"given":"Marija","family":"Milinkovic","sequence":"first","affiliation":[{"name":"Department of Pathology, University Clinical Center of Serbia, 11000 Belgrade, Serbia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivan","family":"Soldatovic","sequence":"additional","affiliation":[{"name":"Institute for Medical Statistics and Informatics, Faculty of Medicine, University of Belgrade, 11000 Belgrade, Serbia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vladan","family":"Zivaljevic","sequence":"additional","affiliation":[{"name":"Clinic for Endocrine Surgery, University Clinical Center of Serbia, 11000 Belgrade, Serbia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vesna","family":"Bozic","sequence":"additional","affiliation":[{"name":"Department of Pathology, University Clinical Center of Serbia, 11000 Belgrade, Serbia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5833-6661","authenticated-orcid":false,"given":"Maja","family":"Zivotic","sequence":"additional","affiliation":[{"name":"Institute of Pathology, Faculty of Medicine, University of Belgrade, 11000 Belgrade, Serbia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Svetislav","family":"Tatic","sequence":"additional","affiliation":[{"name":"Institute of Pathology, Faculty of Medicine, University of Belgrade, 11000 Belgrade, Serbia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9708-2089","authenticated-orcid":false,"given":"Dusko","family":"Dundjerovic","sequence":"additional","affiliation":[{"name":"Institute of Pathology, Faculty of Medicine, University of Belgrade, 11000 Belgrade, Serbia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,4,19]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1007\/s12022-022-09704-6","article-title":"Overview of the 2022 WHO Classification of Paragangliomas and Pheochromocytomas","volume":"33","author":"Mete","year":"2022","journal-title":"Endocr. Pathol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1007\/s12022-017-9484-5","article-title":"Update on Adrenal Tumors in 2017 World Health Organisation (WHO) of Endocrine Tumours","volume":"28","author":"Lam","year":"2017","journal-title":"Endocr. Pathol."},{"key":"ref_3","unstructured":"Lloyd, R.V., Osamura, R.Y., Kloppel, G., and Rosai, J. (2017). WHO Classification of Tumours of Endocrine Organs: Pathology and Genetics of Tumours of Endocrine Organ, IARC Press. [4th ed.]."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1245\/s10434-013-2942-5","article-title":"Inherited mutations in pheochromocytoma and paraganglioma: Why all patients should be offered genetic testing","volume":"20","author":"Fishbein","year":"2013","journal-title":"Ann. Surg. Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1038\/nrc3648","article-title":"Pheochromocytoma and paraganglioma pathogenesis: Learning from genetic heterogeneity","volume":"14","author":"Dahia","year":"2014","journal-title":"Nat. Rev. Cancer"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1210\/jc.2014-1498","article-title":"Pheochromocytoma and paraganglioma: An endocrine society clinical and practice guideline","volume":"99","author":"Lenders","year":"2014","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1177\/107327481101800205","article-title":"Changing paradigms in the treatment of malignant pheochromocytoma","volume":"18","author":"Grogan","year":"2011","journal-title":"Cancer Control"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1055\/s-0029-1220687","article-title":"Novel and evolving therapies in the treatment of malignant pheochromocytoma: Experience with the mTOR inhibitor everolimus (RAD001)","volume":"41","author":"Druce","year":"2009","journal-title":"Horm. Metab. Res."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1053\/ejso.2002.1413","article-title":"The management of benign and malignant pheochromocytoma and abdominal paraganglioma","volume":"29","author":"Elder","year":"2003","journal-title":"Eur. J. Surg. Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.5858\/2008-132-1272-PAEPU","article-title":"Pheochromocytoma and extra-adrenal paraganlioma: Updates","volume":"132","author":"Tischler","year":"2008","journal-title":"Arch. Pathol. Lab. Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1210\/jc.2010-1946","article-title":"Clinical risk factors for malignancy and overall survival in patients with pheochromocytomas and sympathetic paragangliomas; primary tumor size and primary tumor location as prognostic indicators","volume":"96","author":"Feng","year":"2011","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"3296","DOI":"10.1210\/jc.2017-00992","article-title":"Malignant Pheochromocytoma and Paraganglioma: 272 Patients Over 55 Years","volume":"102","author":"Hamidi","year":"2017","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"101354","DOI":"10.1016\/j.beem.2019.101354","article-title":"Metastatic pheochromocytoma and paraganglioma: Management of endocrine manifestations, surgery and ablative procedures, and systemic therapies","volume":"34","author":"Jasim","year":"2020","journal-title":"Best Pract. Res. Clin. Endocrinol. Metab."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1007\/s12022-011-9188-1","article-title":"Diagnostic tests and biomarkers for pheochromocytoma and extra-adrenal paraganglioma: From routine laboratory methods to disease stratification","volume":"23","author":"Eisenhofer","year":"2012","journal-title":"Endocr. Pathol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1097\/00000478-200205000-00002","article-title":"Pheochromocytoma of the Adrenal gland Scaled Score (PASS) to separate benign from malignant neoplasms: A clinicopathologic and immunophenotypic study of 100 cases","volume":"26","author":"Thompson","year":"2002","journal-title":"Am. J. Surg. Pathol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"587779","DOI":"10.3389\/fendo.2020.587779","article-title":"Histopatological Analysis of Tumor Microinviroment and Angiogenesis in Pheochromocytoma","volume":"11","author":"Gao","year":"2020","journal-title":"Front. Endocrinol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1097\/PAS.0b013e318190d12e","article-title":"Observer variation in the application of the Pheochromocytoma of the Adrenal Gland Scaled Score","volume":"33","author":"Wu","year":"2009","journal-title":"Am. J. Surg. Pathol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/j.surg.2008.02.007","article-title":"Prognostic indicators of malignancy in adrenal pheochromocytomas: Clinical, histopathologic and cell cycle\/apoptosis gene expression analysis","volume":"143","author":"Strong","year":"2008","journal-title":"Surgery"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"10931","DOI":"10.1016\/S0021-9258(19)49853-0","article-title":"Angiogenesis","volume":"267","author":"Folkman","year":"1992","journal-title":"J. Biol. Chem."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1016\/S0039-6060(96)80037-7","article-title":"Tumor angiogenesis in pheochromocytomas and paragangliomas","volume":"120","author":"Liu","year":"1996","journal-title":"Surgery"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1046\/j.1464-410x.2001.00102.x","article-title":"Tumour angiogenesis and Ki67 expression in phaeochromocytoma","volume":"87","author":"Ohji","year":"2001","journal-title":"BJU Int."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1210\/clinem\/dgac677","article-title":"TNM Staging and Overall Survival in Patients With Pheochromocytoma and Sympathetic Paraganglioma","volume":"108","author":"Jimenez","year":"2023","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/00129039-200203000-00001","article-title":"Tissue microarrays: A powerful tool for high-throughput analysis of clinical specimens: A review of the method with validation data","volume":"10","author":"Skacel","year":"2002","journal-title":"Appl. Immunohistochem. Mol. Morphol."},{"key":"ref_24","unstructured":"Taylor, C.R., and Rudbeck, L. (2013). Immunohistochemical Staining Methods, Dako Denmark A\/S. [6th ed.]."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1038\/nmeth.2019","article-title":"Fiji: An open-source platform for biological-image analysis","volume":"9","author":"Schnidein","year":"2012","journal-title":"Nat. Methods"},{"key":"ref_26","unstructured":"(2021, November 20). Cell Counts: Histology Guidance (SXHL288). Available online: https:\/\/www.studocu.com\/en-gb\/document\/the-open-university\/cell-biology\/cell-counts-histology-guidance-sxhl288\/6880909."},{"key":"ref_27","unstructured":"(2021, November 20). Exercise 3\u2014Biology 105 Estimating the Size of Cells Using a Compound Light Microscope. Available online: https:\/\/pdf4pro.com\/view\/exercise-3-biology-105-estimating-the-size-of-cells-4aac9.html."},{"key":"ref_28","first-page":"39","article-title":"Endoglin (CD105) expression in angiogenesis of primary hepatocellular carcinomas: Analysis using tissue microarrays and comparisons with CD34 and VEGF","volume":"37","author":"Yao","year":"2007","journal-title":"Ann. Clin. Lab. Sci."},{"key":"ref_29","first-page":"1216","article-title":"Quantitation of sinusoid-like vessels in hepatocellular carcinoma: Its clinical and prognostic significance","volume":"26","author":"Tanigawa","year":"1997","journal-title":"Hepatology"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1007\/BF00666038","article-title":"Current pathologic methods for measuring intratumoral microvessel density within breast carcinoma and other solid tumors","volume":"36","author":"Weidner","year":"1995","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1007\/BF03345807","article-title":"Malignant pheochromocytoma: Clinical, biological, histologic and therapeutic data in a series of 20 patients with distant metastases","volume":"15","author":"Schlumberger","year":"1992","journal-title":"J. Endocrinol. Investig."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1046\/j.1365-2265.1996.657475.x","article-title":"The diagnosis of malignancy in phaeochromocytoma","volume":"44","author":"Pattarino","year":"1996","journal-title":"Clin. Endocrinol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"104129","DOI":"10.1155\/2014\/104129","article-title":"Study of microvessel density and the expression of vascular endothelial growth factors in adrenal gland pheochromocytomas","volume":"2014","author":"Bialas","year":"2014","journal-title":"Int. J. Endocrinol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1016\/S0002-9440(10)64400-8","article-title":"Angiogenesis and vascular architecture in pheochromocytomas: Distinctive traits in malignant tumors","volume":"161","author":"Favier","year":"2002","journal-title":"Am. J. Pathol."},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Oudijk, L., van Nederveen, F., Badoual, C., Tissier, F., Tischler, A.S., Smid, M., Gaal, J., Lepoutre-Lussey, C., Gimenez-Roqueplo, A.-P., and Dinjens, W.N.M. (2015). Vascular pattern analysis for the prediction of clinical behaviour in pheochromocytomas and paragangliomas. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0121361"},{"key":"ref_36","first-page":"1031","article-title":"Long-lasting complete inhibition of human solid tumors in SCID mice by targeting endothelial cells of tumor vasculature with antihuman endoglin immunotoxin","volume":"3","author":"Seon","year":"1997","journal-title":"Clin. Cancer Res."},{"key":"ref_37","first-page":"15","article-title":"Characteristics and possible function of endoglin, a TGF-beta binding protein","volume":"92","author":"Westphal","year":"1993","journal-title":"Behring Inst. Mitt."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1097\/01.PGP.0000070852.25718.37","article-title":"Endoglin (CD105) expression in endometrial carcinoma","volume":"22","author":"Saad","year":"2003","journal-title":"Int. J. Gynecol. Pathol."},{"key":"ref_39","first-page":"417","article-title":"Endoglin is a better marker than CD31 in evaluation of angiogenesis in glioblastoma","volume":"46","author":"Behrem","year":"2005","journal-title":"Croat. Med. J."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"3498","DOI":"10.1182\/blood-2007-08-105346","article-title":"Transcription factor Erg regulates angiogenesis and endothelial apoptosis through VE-cadherin","volume":"111","author":"Birdsey","year":"2008","journal-title":"Blood"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1016\/j.beem.2010.10.004","article-title":"Pheochromocytomas: The (pseudo)-hypoxia hypothesis","volume":"24","author":"Favier","year":"2010","journal-title":"Best Pract. Res. Clin. Endocrinol. Metab."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1159\/000457479","article-title":"Hypoxia Pathway Mutations in Pheochromocytomas and Paragangliomas","volume":"150","author":"Peixoto","year":"2016","journal-title":"Cytogenet. Genome Res."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1007\/s00423-011-0850-3","article-title":"Malignant pheochromocytoma: New malignancy criteria","volume":"397","author":"Oragano","year":"2012","journal-title":"Langenbecks Arch. Surg."},{"key":"ref_44","first-page":"1107","article-title":"Immunohistohemical estimation of growth activity to predict biological behavior of pheochromocytomas","volume":"12","author":"Nagura","year":"1999","journal-title":"Mod. Pathol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1038\/modpathol.3800160","article-title":"CGH and CD44\/MIB-1 immunohistochemisty are helpful to distinguish metastasized from nonmetastasized sporadic pheochromocytomas","volume":"17","author":"August","year":"2004","journal-title":"Mod. Pathol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1097\/01.MP.0000056982.07160.E3","article-title":"KI67 AND hTERT expression can aid in distinction between malignant and benign pheochromocytoma and paraganglioma","volume":"16","author":"Elder","year":"2003","journal-title":"Mod. Pathol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.prp.2010.01.007","article-title":"Immunohistochemical expression of Ki-67, c-erbB-2, and c-kit antigens in benign and malignant pheochromocytoma","volume":"206","author":"Tavangar","year":"2010","journal-title":"Pathol. Res. Pract."},{"key":"ref_48","first-page":"198","article-title":"Distinction between benign and malignant pheochromocytomas","volume":"33","author":"Liu","year":"2004","journal-title":"Zhonghua Bing Li Xue Za Zhi"},{"key":"ref_49","first-page":"484","article-title":"S100 protein-positive sustentacular cells in malignant and locally aggressive adrenal pheochromocytomas","volume":"115","author":"Unger","year":"1991","journal-title":"Arch. Pathol. Lab. Med."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"101416","DOI":"10.1016\/j.beem.2020.101416","article-title":"An overview of 20 years of genetic studies in pheochromocytoma and paraganglioma","volume":"34","author":"Buffet","year":"2020","journal-title":"Best Pract. Res. Clin. Endocrinol. Metab."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1136\/jmg.39.3.178","article-title":"Prevalence of SDHB, SDHC, and SDHD germline mutations in clinic patients with head and neck paragangliomas","volume":"39","author":"Baysal","year":"2002","journal-title":"J. Med. Genet."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1055\/s-0032-1304594","article-title":"A decade (2001\u20132010) of genetic testing for pheochromocytoma and paraganglioma","volume":"44","author":"Buffet","year":"2012","journal-title":"Horm. Metab. Res."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"T91","DOI":"10.1530\/ERC-15-0268","article-title":"15 YEARS OF PARAGANGLIOMA: Clinical manifestations of paraganglioma syndromes types 1\u20135","volume":"22","author":"Benn","year":"2015","journal-title":"Endocr. Relat. Cancer"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"G1","DOI":"10.1530\/EJE-16-0033","article-title":"European Society of Endocrinology Clinical Practice Guideline for long-term follow-up of patients operated on for a phaeochromocytoma or a paraganglioma","volume":"174","author":"Plouin","year":"2016","journal-title":"Eur. J. Endocrinol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1016\/S1470-2045(09)70164-0","article-title":"An immunohistochemical procedure to detect patients with paraganglioma and pheochromocytoma with germline SDHB, SDHC, or SDHD gene mutations: A retrospective and prospective analysis","volume":"10","author":"Gaal","year":"2009","journal-title":"Lancet Oncol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1097\/00000658-199906000-00001","article-title":"Clinical experience over 48 years with pheochromocytoma","volume":"229","author":"Goldstein","year":"1999","journal-title":"Ann. Surg."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1055\/s-0029-1231025","article-title":"Treatment of malignant pheochromocytoma","volume":"41","author":"Ajalle","year":"2009","journal-title":"Horm. Metab. Res."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"8812","DOI":"10.1200\/JCO.2005.03.1484","article-title":"Genetic testing in pheochromocytoma of functional paraganglioma","volume":"23","author":"Amar","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"587769","DOI":"10.3389\/fendo.2020.587769","article-title":"Recent advances in histopathological and molecular diagnosis in pheochromocytoma and paraganglioma: Challenges fo predicting metastasis in individual patients","volume":"11","author":"Yamazaki","year":"2020","journal-title":"Front. Endocrinol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1530\/ERC-13-0494","article-title":"Phaechromocytoma Study Group in Japan. Pathological grading in phaechromocytoma and paraganglioma","volume":"21","author":"Kimura","year":"2014","journal-title":"Endocr Relat Cancer"},{"key":"ref_61","first-page":"769","article-title":"The systems of metastatic potential prediction in pheochromocytoma and paraganglioma","volume":"10","author":"Wang","year":"2020","journal-title":"Am. J. Cancer"},{"key":"ref_62","doi-asserted-by":"crossref","unstructured":"Koh, J.-M., Ahn, S.H., Kim, H., Kim, B.-J., Sung, T.-Y., Kim, Y.H., Hong, S.J., Song, D.E., and Lee, S.H. (2017). Validation of pathological grading systems for predicting metastatic potential in pheochromocytoma and paraganglioma. PLoS ONE, 12.","DOI":"10.1371\/journal.pone.0187398"}],"container-title":["Diagnostics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2075-4418\/14\/8\/849\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T14:31:13Z","timestamp":1760106673000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2075-4418\/14\/8\/849"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,19]]},"references-count":62,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2024,4]]}},"alternative-id":["diagnostics14080849"],"URL":"https:\/\/doi.org\/10.3390\/diagnostics14080849","relation":{},"ISSN":["2075-4418"],"issn-type":[{"value":"2075-4418","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,19]]}}}